4.8 Article

Multilayers enzyme-coated carbon nanotubes as biolabel for ultrasensitive chemiluminescence immunoassay of cancer biomarker

Journal

BIOSENSORS & BIOELECTRONICS
Volume 24, Issue 10, Pages 2961-2966

Publisher

ELSEVIER ADVANCED TECHNOLOGY
DOI: 10.1016/j.bios.2009.03.002

Keywords

Carbon nanotube; Layer-by-layer; Horseradish peroxidase; Chemiluminescence immunoassay

Funding

  1. Excellent Young Scientists Foundation of Shandong Province [JQ200805]
  2. University Doctoral Foundation of the Ministry of Education [200804260001]
  3. National Nature Science Foundation of China [20775038, 20827005]

Ask authors/readers for more resources

A novel and ultrasensitive chemiluminescence immunoassay (CLIA) method based on multiple enzyme layers assembled multiwall carbon nanotubes (MWCNTs) as signal amplification labels was developed by employing luminol-H2O2-HRP-bromophenol blue (BPB) enhanced chemiluminescence (CL) system for the detection of a cancer biomarker in human serum samples, as exemplified by the measurement of alpha-fetoprotein (AFP) as a model protein. In this study, horseradish peroxidase (HRP) was assembled onto MWCNTs templates layer-by-layer (LBL) through electrostatic interactions with polyion PDDA, and further conjugated with AFP secondary antibodies (Ab(2)) as the enzyme label. The resulting LBI. assembly could maximize the ratio of HRP/Ab(2) which Could amplify the sensitivity greatly. To the best of our knowledge, it was the first time for this strategy applied in CLIA to date. Under the optimum conditions of luminol-H2O2-HRP-BPB CL system and the sandwich immunoreactions, a linear range from 0.02 to 2.0 ng/mL (R=0.9980) was obtained with the detection limit of 8.0 pg/mL (3 sigma) which was two orders of magnitude lower than standard ELISA method. Furthermore, accurate detection of AFP in human Serum samples was also demonstrated by comparison to ELISA assays. From the above results, such signal amplification strategy proposed by the novel CNT-LBL enzyme label showed all excellent promise for ultrasensitive detection of cancer biomarkers in clinical laboratory. (C) 2009 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available